Highlighted Achievements 

March 22, 2024
Amal Amer, MD, PhD, professor of microbial infection and immunity in the College of Medicine, has earned The Ohio State University 2024 Distinguished Scholar Award.

Highlighted Publications

January 3, 2024
A bacterial pigment provides cross-species protection from H2O2- and neutrophil-mediated killing
Yiwei Liu, Eleanor A. McQuillenc, Pranav S. J. B. Rana, Erin S. Gloag, Matthew R. Parseke, Daniel J. Wozniak
Published in The Proceedings of the National Academy of Sciences (PNAS). PMID: 38170744

April 1, 2023
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor
Shuzhong Zhang, Chandra L. Shrestha, Frank Robledo-Avila, Devi Jaganathan, Benjamin L. Wisniewski, Nevian Brown, Hanh Pham, Katherine Carey, Amal O. Amer, Luanne Hall-Stoodley, Karen S. McCoy, Shasha Bai, Santiago Partida-Sanchez, Benjamin T. Kopp
Published in The European Respiratory Journal. PMID: 36265882

July 12, 2022
Assemblies of JAG1 and JAG2 determine tracheobronchial cell fate in mucosecretory lung disease
Susan D. Reynolds, Cynthia L. Hill, Alfahdah Alsudayri, Scott W. Lallier, Saranga Wijeratne, Zheng Hong Tan, Tendy Chiang, Estelle Cormet-Boyaka
Published in The JCI Insight. PMID: 35819850

October 6, 2021
Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA
Yanran Lu, Sandip Vibhute, Linsen Li, Antony Okumu, Steven C. Ratigan, Sheri Nolan, Jonathan L. Papa, Chelsea A. Mann, Anthony English, Anna Chen, Justin T. Seffernick, Bryan Koci, Leonard R. Duncan, Brieanna Roth, Jason E. Cummings, Richard A. Slayden, Steffen Lindert, Craig A. McElroy, Daniel J. Wozniak, Jack Yalowich, and Mark J. Mitton-Fry
Published in The Journal Medicinal Chemistry. PMID: 34614347

May 28, 2020
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter,
Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard,
Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, on behalf of the VX17-445-103 Trial Group†
Published in The Lancet. PMID: 31679946

Upcoming Events

Full Event Schedule

Core Services

C3 is organized around three biomedical research cores that support ongoing research projects.

Epithelial Production,
​Analysis, and Innovation

Immune

Translational and Data

Grant Opportunities

C3 Training Grant Award:
Grant Application Deadline: 
June 17, 2024 at 5pm

C3 Pilot & Feasibility Award:
Grant Application Deadline: 
Closed

View More

Our Research

C3 researchers have many exciting collaborative projects aimed at understanding the interplay of host immunity, infection, and inflammation in persons with CF.

Members

Publications

Karen McCoy, MD​

Program Co-Director
​Nationwide Children's Hospital
Email

Daniel Wozniak, PhD​

Program Co-Director
​The Ohio State University
Email